For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.
Percentage of γδ T cells increased in multiple myeloma patients. (A) gating for γδ T cells in multiple myeloma patients; (B) gating for γδ T cells in healthy controls. - Increased CD8⁺ T cells (P < ...
Bicistronic CD19/CD22-directed CAR-T cell therapy achieved high remission rates and durable responses in pediatric B-ALL patients. One-year EFS and OS rates were 75.5% and 93.5%, respectively, with ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...
Colorectal cancer can be treated using immunotherapy approaches that use the immune cells to target cancer cells and induce the killing of those cancer cells. Some colorectal cancer types have been ...
Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results